Celleron Therapeutics is a biopharmaceutical company focusing on new and innovative cancer treatments.
Celleron’s Vision is to build a global pipeline of clinical products which are safe and effective in unmet indications, supported by a precision medicine platform.
It has two registrational study assets, zabinostat and emactuzumab, which offer near term revenues. It is also in active discussion with major multinational pharmaceutical companies to acquire new assets for clinical development and commercialisation.
Professor Nick La Thangue
MA MSc PhD FRSE FMedSci
Chief Executive Officer
Nick has over 30 years of experience in biotech entrepreneurship, translational cancer science and drug development. He founded Prolifix focused on cell cycle therapeutics, where he acted as CSO and CEO until its merger with TopoTarget which led to a highly successful IPO. He founded Oxford Cancer Biomarkers, which continues to develop a portfolio of marketed precision cancer medicine tests, where he held senior positions including CEO and CSO. He has been CEO at Celleron Therapeutics developing precision cancer drugs since the company was founded. Nick is Professor of Cancer Biology at Oxford University. He is a Fellow of the Royal Society of Edinburgh, the Academy of Medical Sciences, the European Academy of Cancer Science, the Lister Institute and Professorial Fellow of Linacre College Oxford. He has over 200 publications and is an inventor on numerous patents.
Professor David Kerr
CBE MA MSc MD PhD DSc FRCP FRCGP FACP FMedSci
Chief Medical Officer
David is a senior clinician with more than 30 years experience in cancer treatment. He has a strong record in clinical research and has built numerous life sciences companies over the years, including Cobra, Therexsys, Oxford Cancer Biomarkers, Celleron and SynOx Therapeutics. David contributes to Oxford as Professor of Cancer Medicine, where he has worked with colleagues to build a new Institute for Cancer Medicine and Cancer Hospital. He is an Honorary Professor of Oncology in Sichuan, Suchow, Xiamen, Shanghai, and Seoul National Universities. He has published over 400 papers and has an H-Index of 95 associated with over 45,000 citations. He was elected President of the European Society of Medical Oncology in 2010. He is Editor in Chief of The Oxford Textbooks of Oncology and Cancer Biology, was Editor in Chief of Annals of Oncology, established the Journal of Global Oncology and has initiated a new course in Oxford on Global Health Diplomacy.
MA (Law) ACMA
Chief Financial Officer
Bill’s career spans over 25 years in a broad range of finance positions. Holding a law degree from Cambridge University and as a qualified ACMA, Bill has accumulated international FD/CFO experience in small venture-backed companies and large blue chips. Bill served as European Finance Director for Visible Genetics, a pioneering company in the field of nucleic acid diagnostics, subsequently holding senior finance positions for Bayer Healthcare in Europe and the USA. Bill played a leading role in securing investment for Oxford University spinout Oxitec and in its successful acquisition by Intrexon Corporation. Bill actively supports the Biotech industry with roles including Chair of OBN, and engagements with Celleron Therapeutics, Grey Wolf Therapeutics and Ultromics Ltd.
Collette a highly qualified and experienced business leader. She has held several management positions in both industry and academia throughout her career. Her recent experience includes knowledge and technology transfer in several Oxford University spinouts and patent portfolio management. She demonstrates leadership in strategic planning and implementation of cross-functional corporate and business activities.
MSc CSci MIBMS
Clinical Research Director
Simon Cook is a Chartered Scientist and Member of the Institute of Biomedical Sciences, with 32 years of experience in running international clinical trials in all phases (I-IV). Initially graduating in Pharmacology from the University of Strathclyde, he has since become a specialist in the management of commercial drug development to GCP standards and has written two books on the subject. He began his career with manufacturers such as Beechams (now GSK) and then crossed into the CRO business: managing clinical trials at companies such as G H Besselaar Associates (now Covance), Quintiles (now IQVIA), and Kendle International (now Syneos Health). Since 2016 he has specialised in researching novel anti-cancer agents within the biotech sector, at Celleron Therapeutics, Oxford; and latterly SynOx Therapeutics.
Shawn S Zheng
DPhil MBA FRSB
Business and Development Director
Shawn is a business development professional with experience spanning across a number of Oxford University spinouts, including SynOx, Celleron, and Argonaut Therapeutics. He has a strong background in cancer research and was formerly a principal investigator of a joint drug discovery programme between MSD and A*STAR Singapore. Shawn was educated at the Universities of Oxford and Cambridge where he received his DPhil and MBA degrees, respectively, and underwent postdoctoral training with Sir David Lane FRS. He is a lead author in a number of top-tier scientific publications and a recipient of multiple prestigious scholarships. He is a Visiting Fellow at Linacre College Oxford and an elected Fellow of the Royal Society of Biology.
James Noble MA FCA has held a number of high-profile positions in his long and successful career in the Biotech sector, most recently as Co-Founder and CEO of Adaptimmune Therapeutics. He was also the founding CEO of Immunocore Ltd. James currently serves as a non-executive director of Adaptimmune and is Deputy Chairman of NASDAQ-listed GW Pharmaceuticals. Prior to that, James held a wide range of non-executive roles, including on the Boards of Medigene, Powderject and Oxford Glycosciences. He was previously CFO at British Biotech, where he took the company public in London and on NASDAQ and was formerly a director at the investment bank, Kleinwort Benson. James has extensive experience of both private and public sector markets.
Professor Douglas Manion
Doug has 20 years experience in drug development. He was the Senior Vice President, Head of Specialty Development and Head of Japan and China R&D at BMS until October 2016. He had leadership roles at BMS overseeing various therapeutic areas including virology, immunoscience, neurology, cardiology, metabolic diseases, genetically-defined diseases and fibrosis since joining in 2005. From 2001 to 2005, he was Vice President of Clinical Development and Medical Affairs for HIV/AIDS at GSK. He started his career at DuPont Pharmaceuticals in 1997. He is Board Certified in Internal Medicine and completed his Fellowship in Infectious Diseases in Ottawa Canada and a clinical and bench research fellowship at Massachusetts General Hospital and Harvard Medical School.
Sangwoo is the Director of Korean Investment Partner’s US offices, based in Silicon Valley, with worldwide experience in development of investment portfolios. Sangwoo has 18 years industry experience, prior to this, both in corporate and new venture environments, including roles with Samsung Electronics, Dasan Networks, Neomtel and Polidigm.
Ji Woong Chun
Ji Woong is a Healthcare Venture Investment Team Leader in KTB Network, and on the Board of Directors of several biotech companies. Previously, he was in Daiichi Sankyo as a Global Clinical Study Manager. He has a Masters Degree from Seoul National University, and a Pharmacy Degree from Kyung Sung University.
Dr Chris Towler
Chris Towler was educated in the life sciences, gaining a PhD in Biochemistry and undertaking a number of years of post-doctoral research in the area of onco-foetal antigens. He then spent 23
years in the Pharmaceutical Industry (Glaxo and GlaxoWellcome), 13 of which were as leader of a project management organisation within the Development Directorate, followed by a period as head of International and Manufacturing Regulatory Affairs. Chris led the development teams responsible for bringing a number of major novel therapies (including Imigran, Zofran and Relenza) to the market, served as a member of the Corporate Strategy Team and was closely involved with organisational change and post-merger integration projects.
Professor Declan Doogan
Chief Scientific and Clinical Advisor
Declan has 30 years experience in drug development and has worked with a number of new drug development companies. He was the Global Head of Development at Pfizer until he retired from that role in 2007. Since then Declan has been President of R&D and then CEO at Amarin. He is currently the CEO of Portage Biotech, a portfolio company developing new drugs using novel protein transporters and the Chair of Biohaven, a spin out from Yale that specialises in psychiatric diseases. He has held a number of visiting professorships at Harvard School of Public Health, Glasgow University Medical School and Kitasato University (Tokyo), where he has been involved with development of strategies to enhance efficiency of the R&D process.
Celleron has acquired global rights to zabinostat (CXD101) through an exclusive world-wide license agreement from AstraZeneca
SynOx Therapeutics (a Celleron spin-out) has acquired global rights to emactuzumab through an exclusive world-wide license agreement from Roche
Celleron and MSD have an existing agreement with University College London (UCL) to provide zabinostat and pembrolizumab for clinical studies in diffuse large B-cell lymphoma (DLBCL)
Celleron has a sub-licensing and partnership agreement with Nuance Biotech to develop zabinostat in China and South Africa
Celleron has signed a memorandum of understanding (MOU) with Genor Biopharma relevant to the clinical development of zabinostat
Celleron has established a unique partnership with Oxford University Hospitals NHS Trust to facilitate its clinical trials and develop its precision medicine platform
SynOx Therapeutics is a Celleron spin-out with a focus to deliver marketing approval for emactuzumab in diffuse tenosynovial giant cell tumour.
In December 2020, SynOx acquired a world-wide exclusive license for emactuzumab from Roche, and received €37 million investment from HealthCap, Medicxi, Forbion and Gimv.
It is currently engaging in an Orphan Registration Trial for emactuzumab.